GOCARDLESS
4.5.2022 01:03:13 CEST | Business Wire | Press release
GoCardless , a leader in direct bank payment solutions, today announced the appointment of Paul Stoddart as President. Stoddart joins from Mastercard where he was President of its New Payment Platforms, Executive Chairman of Vocalink and a Member of the Mastercard Management Committee. In his new role at GoCardless he will have global responsibility for the go-to-market organisation including the Strategy, Sales, Product, Marketing and Customer teams, with a view to accelerating growth and achieving the company’s ambition to become the world’s bank payment network.
Stoddart brings a wealth of experience to GoCardless. He was named as Chief Executive Officer of Vocalink after its acquisition by Mastercard and subsequently promoted to President of Mastercard’s New Payment Platforms where he led the establishment and growth of a business unit that expanded Mastercard’s role in payments beyond cards to account-to-account payments. Prior to Vocalink he was Co-Head of Corporate Finance at Barclaycard. He also spent 10 years at NatWest where he held a number of senior roles including in their merchant acquiring and e-commerce business, Worldpay.
His appointment comes as the company broadens its offering of direct bank payment solutions for both one-off and recurring payments and builds out its suite of payment intelligence products to help businesses manage their payments more effectively. GoCardless will benefit from Stoddart’s expertise as it doubles down on account-to-account payments, with plans to release its Variable Recurring Payment feature shortly in the UK and expand Instant Bank Pay, its solution for one-off payments, across Europe.
Hiroki Takeuchi, co-founder and CEO at GoCardless, said : “This year marks an inflection point at GoCardless as we expand beyond recurring payments to serve a broader range of customer segments and payment use cases. Having the right people to lead us on this journey is critical as we scale our business, develop new products and services with open banking, and explore new markets. Paul has a unique depth of experience across both card and non-card payments and is well-positioned to help us seize the opportunities that will make GoCardless a force to be reckoned with in the payments space.”
Paul Stoddart, President at GoCardless, said: “GoCardless is in an incredibly exciting place right now. Hiroki and the team have already built a successful business by solving real customer problems. They have the foundations of a global bank pay network that will go from strength to strength as more businesses and people embrace account-to-account payments from bank debit to open banking-enabled payments. We will continue to push the boundaries of what’s possible in payments. In this new role at GoCardless I’ll have the opportunity to be part of the team building the new generation of payment solutions to do just that, with customer needs at the forefront.”
Stoddart’s appointment comes as GoCardless continues to accelerate its growth following its latest funding round of US$312 million in February. In the intervening months, GoCardless released its second open banking-enabled feature, Verified Mandates, in the UK and Success+, its ‘payment intelligence’ product which uses machine learning to identify the optimal day to recover failed payments, in the US.
In the UK, GoCardless recently signed its first Variable Recurring Payment customers and plans to introduce VRPs in both ‘sweeping’ and ‘non-sweeping’ forms over the coming months. By mid-2022, GoCardless will also integrate PayTo into its global bank payment platform in time for the regulated launch in Australia.
About GoCardless
GoCardless is a global leader in direct bank payment solutions, making it easy to collect both recurring and one-off payments directly from customers' bank accounts through direct debit and open banking. The GoCardless global payments network and technology platform take the pain out of getting paid for 70,000 businesses worldwide, from multinational corporations to small businesses. Each year GoCardless processes over US$30 billion of payments across more than 30 countries. GoCardless is headquartered in the UK, with additional offices in Australia, France, Germany and the United States. For more information, please visit www.gocardless.com and follow us on Twitter @GoCardless .
© 2022 GoCardless Ltd. All Rights Reserved. GoCardless is a registered trademark of GoCardless Ltd. in multiple countries. Third party trademarks mentioned above are owned by their respective companies. Unless explicitly identified as such, nothing in this press release should be construed to the contrary, or as an approval, endorsement or sponsorship by any third parties of GoCardless Ltd. or any aspect of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006146/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
